Good morning,
We have thirteen deals this week, taking in a €63 million sale-and-leaseback in Amsterdam, Flagship Pioneering's arrival at King's Cross and a €25 million distribution hub for Ireland's life sciences supply chain. Let's dive in.
In today's free edition:
🇳🇱 Remake Asset Management acquires Plesmanlaan life sciences complex in Amsterdam for €63 million
🇬🇧 Flagship Pioneering takes space at LBIC: Apex on Tribeca's King's Cross campus
🇮🇪 Thermo Fisher Scientific opens €25 million distribution centre in County Meath
🇫🇷 One Biosciences takes full floor at The Hive laboratory building in Villejuif
🔒 For paying members only:
🇬🇧 Life Sciences Innovation Hub launches in Dundee
🇩🇪 Gateway Factory and Cellcolab open coworking lab in Cologne
🇬🇧 £21 million medical training centre in Birmingham
🇳🇱 ICAT joins Plus Ultra Utrecht at Utrecht Science Park
🇳🇱 GenScript opens mRNA production site at Biotech Campus Delft
🇬🇧 Sciontec unveils HEMISPHERE at Paddington Village, Liverpool
🇩🇪 TSC Real Estate acquires healthcare property in Friedberg
🇮🇪 Pharmacy unit at 16.3 per cent yield
🇬🇧 T-Cypher Bio takes new laboratory space at Abingdon
Subscribe here to unlock.
Enjoy today's newsletter,
— Stephen Ryan (connect with me on LinkedIn)
Remake Asset Management acquires Plesmanlaan life sciences complex in Amsterdam
Remake Asset Management has acquired a 15,760 sq m life sciences complex at Plesmanlaan 125 in Amsterdam Nieuw‑West from Prothya Biosolutions via a sale‑and‑leaseback.
Prothya, a plasma‑derived medicines producer now part of Intas subsidiary Accord Plasma, retains the entire facility on a long‑term triple‑net lease.
Market sources indicate an implied capital value of approximately €62.5–63 million, equating to around €3,956 per sq m and reflecting a net initial yield in the region of 7.1%.
Knight Frank (NL real estate), Greenberg Traurig and Drees & Sommer advised Remake, while Cushman & Wakefield and DLA Piper acted for Prothya.
Flagship Pioneering takes space at LBIC: Apex

Flagship Pioneering has taken space within LBIC: Apex at The Apex building, the first laboratory building at the Tribeca life sciences campus in King's Cross, offering around 112,500 sq ft of lab-enabled space across six floors as part of a one million sq ft, five‑building development on Regent's Canal.
The LBIC: Apex facility provides fully fitted CL2 grow‑on laboratories and write‑up suites from roughly 840 sq ft to 3,700 sq ft, complementing LBIC's original Camden campus and contributing to London's largest purpose-built life science cluster anchored by Tribeca and the Francis Crick Institute.
In addition to this newsletter, we deliver bespoke research and strategic analysis for investors and developers — from acquisition support to market mapping and custom reporting. Hit reply to discuss your next project.
Thermo Fisher Scientific opens €25 million distribution centre in County Meath
Thermo Fisher Scientific has opened a €25 million, 6,503 sq m distribution centre in Bracetown, County Meath.
The purpose-built facility increases the company's in-country distribution capacity by more than 400 per cent, enabling supply and storage of products supporting drug discovery research, clinical development and commercial manufacturing.
The investment strengthens supply chain resilience for Ireland's life sciences sector and enhances local access to critical materials, chemicals and temperature-sensitive products.
One Biosciences takes full floor at The Hive laboratory building in Villejuif

Biotechnology company One Biosciences has taken the full seventh floor of The Hive, a 25,000 sq m laboratory and office building on the Grand Parc Campus in Villejuif.
The company, a spin-off from the Institut Curie co-founded with Home Biosciences, specialises in precision oncology using single-cell transcriptomic analysis and artificial intelligence.
Founded in 2020, it raised €15 million in a Series A round in July 2025, bringing total funding to over €20 million. The building is operated by Kadans Science Partner.
👇 As a free member, you're seeing only 4 of 13 deals this week. Subscribers see them all — why not take a 14-day trial?